Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
Clinical Lymphoma Myeloma and Leukemia · 2025-01 · 25 (1) · e34-e39
DOI: 10.1016/j.clml.2024.08.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-01. Verfasst von Massimo Breccia und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Università Sapienza, Rome, Italy. Electronic address: breccia@bce.uniroma1.it. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In the last decade, TKIs improved the overall survival (OS) of chronic myeloid leukemia (CML) patients who achieved a deep and sustained molecular response (DMR, defined as stable MR4 and MR4.5). Those patients may attempt therapy discontinuation. In our analysis, we report the differences in eligibility criteria due to time of response and different TKI used as frontline treatment analyzed in a large cohort of CP-CML patients. METHODS: Data were exported by LabNet CML, a network founded by GIMEMA in 2014. The network standardized and harmonized the molecular methodology among 51 laboratories distributed all over Italy for the diagnosis and molecular residual disease (MRD) monitoring. RESULTS: Out of 1777 patients analyzed, 774 had all evaluable timepoints (3, 6, and 12 months). At 3 months, 40 patients obtained ≥MR4: of them 14 (3.6%) with imatinib, 8 (5.8%) with dasatinib, and 18 (7.4%) with nilotinib (P = .093); at 6 months, 146 patients were in MR4: 42 (11%) with imatinib, 38 (28%) with dasatinib, and 66 (27%) with nilotinib (P 2 years was significant for patients who at 3 months had ≥MR2 (18% vs. 9.9% of pts with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Università Sapienza, Rome, Italy. Electronic address: breccia@bce.uniroma1.it.
- GIMEMA Data Center, Rome, Italy.
- Department of Hematology, Istituto Seragnoli, Università di Bologna, Bologna, Italy.
- Department of Hematology, Università di Pisa, Pisa, Italy.
- Department of Hematology, Università Federico II, Napoli, Italy.
- Department of Hematology, Università Cattolica, Roma, Italy.
Zitieren
APA
Breccia, M., Cucci, R., Marsili, G., Castagnetti, F., Galimberti, S., Izzo, B., Sorà, F., Soverini, S., Messina, M., Piciocchi, A., Bonifacio, M., Cilloni, D., Iurlo, A., Martinelli, G., Rosti, G., Stagno, F., Fazi, P., Vignetti, M., & Pane, F. (2025). Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network. Clinical Lymphoma Myeloma and Leukemia, 25(1), e34-e39. https://doi.org/10.1016/j.clml.2024.08.009
Vancouver
Breccia M, Cucci R, Marsili G, Castagnetti F, Galimberti S, Izzo B, et al. Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network. Clinical Lymphoma Myeloma and Leukemia. 2025;25(1):e34-e39. doi:10.1016/j.clml.2024.08.009
BibTeX
@article{Breccia2025,
author = {Breccia, Massimo and Cucci, Rosalba and Marsili, Giovanni and Castagnetti, Fausto and Galimberti, Sara and Izzo, Barbara and Sorà, Federica and Soverini, Simona and Messina, Monica and Piciocchi, Alfonso and Bonifacio, Massimiliano and Cilloni, Daniela and Iurlo, Alessandra and Martinelli, Giovanni and Rosti, Gianantonio and Stagno, Fabio and Fazi, Paola and Vignetti, Marco and Pane, Fabrizio},
title = {Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
volume = {25},
number = {1},
pages = {e34--e39},
doi = {10.1016/j.clml.2024.08.009}
}
EUVIMED